Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Basal Cell 1Melanoma 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1

Interventions

pembrolizumab 16Nivolumab 15Ipilimumab 12cemiplimab 10aldesleukin 6Interleukin-2 6Cyclophosphamide 6fludarabine 5fludarabine phosphate 4encorafenib 4binimetinib 4Blood Specimen Collection 4avelumab 3Sirolimus 3trametinib 2spartalizumab 2lifileucel 2dabrafenib 2atezolizumab 2Vemurafenib 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Prednisone 2Niacinamide 2Exercise 2Everolimus 2Dermoscopy 2Biopsy 2urelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × Risk Factors × 1 year × Clear all
NCT03509467 2025-12-19

Using MC1R Genotype to Impact Melanoma Risk Behavior

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
2,054 enrolled 92 charts
Dermatologic

Carcinoma, Basal Cell, Carcinoma, Squamous Cell, Melanoma, Skin Neoplasms, Neoplasms, Basal Cell, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡